BitMart Misses Roadmap Deadline and Appoints Financial Adviser
CV Sciences director Charlie Cheever buys $114,816 in stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Charlie E. Cheever III, a director and 10% owner of CV Sciences, Inc. (), acquired common stock in the company totaling $114,816 through a series of purchases in late July and early August 2026. The purchases come as the stock trades at $0.02 per share, with the company carrying a market capitalization of just $4.29 million.
According to a recent SEC Form 4 filing, Mr. Cheever purchased a total of 5,740,816 shares of common stock. All acquisitions were made at a price of $0.02 per share.
The transactions occurred on multiple dates:
On July 16, 2026, Mr. Cheever acquired 91,387 shares.
On July 17, 2026, he purchased 749,000 shares.
On July 21, 2026, an additional 335,000 shares were acquired.
On July 22, 2026, he bought 272,500 shares.
On July 24, 2026, 470,075 shares were added.
On July 28, 2026, a purchase of 1,830,000 shares was made.
On July 29, 2026, 60,000 shares were acquired.
On July 31, 2026, he purchased 1,730,000 shares.
On August 4, 2026, 108,000 shares were acquired.
The final reported transaction was on August 7, 2026, with the purchase of 94,854 shares.
The insider buying activity occurs against a challenging backdrop for the stock. According to InvestingPro data, CVSI has declined 58% over the past six months and is down 69% year-to-date. InvestingPro offers 6 additional exclusive tips for CVSI subscribers.
Following these transactions, Mr. Cheever’s direct beneficial ownership in CV Sciences, Inc. increased to 26,648,711 shares of common stock.
In other recent news, CV Sciences reported a decline in revenue for the second quarter of 2026. The company’s revenue fell to $3.0 million, representing a 17% decrease compared to the same period last year and a 7% drop from the previous quarter. Despite the revenue decline, CV Sciences highlighted positive operating cash flow and a strategic expansion beyond cannabinoids. These recent developments reflect ongoing challenges in the CBD market, which have impacted sales. The company has implemented tighter spending measures in response to these conditions. The information was shared during an earnings call, where the company provided insights into its current financial performance. No information regarding analyst upgrades or downgrades was provided in the recent updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
